Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | CETP | P11597 | 4/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7238998 | 0.88 | F2 (0.32) | F2CETPBLMCYP2D6 | |
| SCHEMBL7239144 | 0.83 | BLM (0.34) | F2CETPBLMCYP2D6 | |
| SCHEMBL7247322 | 0.82 | BLM (0.33) | F2CETPBLMCYP2D6 | |
| SCHEMBL7245320 | 0.76 | F2 (0.42) | F2 | |
| SCHEMBL7238843 | 0.73 | MMP2 (0.36) | F2CETPBLMCYP2D6 | |
| SCHEMBL7239284 | 0.72 | F2 (0.34) | F2 | |
| SCHEMBL7106214 | 0.70 | F2 (0.36) | F2CETPBLMCYP2D6 | |
| SCHEMBL7106564 | 0.70 | F2 (0.34) | F2CETPBLMCYP2D6 | |
| SCHEMBL7244218 | 0.67 | F2 (0.32) | F2 | |
| SCHEMBL7243610 | 0.66 | F2 (0.47) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | F2 1/4885CETP 848/4885BLM 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.